Bluebird Bio reported $126.73M in Current Liabilities for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Agios Pharmaceuticals AGIO:US USD 53.6M 5.2M
Alnylam Pharmaceuticals ALNY:US USD 772.79M 115.11M
Amgen AMGN:US USD 15.69B 1.36B
Avrobio Inc AVRO:US USD 16.19M 3.41M
Biogen BIIB:US USD 3.93B 1.09B
Biomarin Pharmaceutical BMRN:US USD 521.02M 56.29M
Bluebird Bio BLUE:US USD 126.73M 22.13M
Gilead Sciences GILD:US USD 11.24B 814M
Immunogen IMGN:US USD 103.64M 16.57M
Intercept Pharmaceuticals ICPT:US USD 221.58M 70.16M
IONIS PHARMACEUT IONS:US USD 283.45M 15.64M
Mirati Therapeutics MRTX:US USD 126.99M 7.84M
Moderna Inc MRNA:US USD 6.81B 5M
Nektar Therapeutics NKTR:US USD 83.99M 21M
Novartis NOVN:VX USD 28.66B 496M
Ptc Therapeutics PTCT:US USD 420.08M 147.29M
Regeneron Pharmaceuticals REGN:US USD 3.85B 969.9M
Sangamo Biosciences SGMO:US USD 122.36M 2.37M
Sarepta Therapeutics SRPT:US USD 602.92M 57.35M
Seattle Genetics SGEN:US USD 726M 117.48M
Ultragenyx Pharmaceutical RARE:US USD 227.36M 6.72M